The Haystack and the Needles

Institutions love silos; revolutions love transparency. For generations, medical research operated under its own kind of feudalism, where laboratories functioned like closed fiefdoms, guarding discoveries behind proprietary gates and expensive paywalls. In 2014, Steve Gleason, a former professional football player living with amyotrophic lateral sclerosis, decided to challenge that entrenched complacency. He convened a historic summit of researchers, technology leaders, and individuals living with ALS to chart a completely open course for clinical discovery. The gathering produced a comprehensive seventeen-page blueprint authored by Dr. Jeffrey Rothstein of the Packard Center at Johns Hopkins and driven by the individuals fighting the condition. That document served as a founding charter, establishing a framework for publicly sharing clinical findings and forcing a fragmented medical establishment to open its gates. Answer ALS grew directly from that initial act of collective defiance. Multiple leaders and institutions across ALS research stepped forward to help further develop the program, transforming it into the largest coordinated collaborative effort ever attempted in the field. What began as a bold challenge to the status quo became an open-source commons of human biology, accelerating discovery, breaking down barriers, and ensuring that no individual is left to face a terminal diagnosis alone.

Funding the massive costs of whole-genome sequencing and industrial biomanufacturing required an unprecedented mobilization of capital. Jay S. Fishman, the Chief Executive Officer of The Travelers Companies, injected vital early momentum following his own diagnosis, utilizing high-profile events like the Travelers Championship golf tournament to secure substantial research funding. Reading of Fishman’s public conviction that Answer ALS was the definitive research effort to back, Peter Warlick, an executive at American Airlines, joined the effort. Warlick mobilized the global aviation sector through his Aviators Against ALS campaign, raising nearly six million dollars to protect the open-access model.

Ed Rapp, the Group President of Caterpillar Inc., joined them following his diagnosis in 2015. Bringing his experience from heavy industry, Rapp approached the sprawling research challenge with a clear analytical vision. “In simple terms, we’re building the haystack and using analytics, AI, and emerging technologies to find the needles,” he explained, targeting the specific genetic pathways that drive the illness. Together, these three executives formed a tight leadership trio, guiding the infrastructure until August 2016, when Fishman passed the baton to Rapp shortly before his death. Serving as the Chair of the Advisory Board for Answer ALS, Rapp keeps the project moving toward aggressive milestones, while his Stay Strong versus ALS initiative continues funding millions of dollars directly into the search for a cure.

Accumulating billions of biological and clinical data points from over one thousand individual lives created a profound logistical challenge. Storing an unprecedented volume of human evidence demanded a technological foundation capable of ensuring global data integrity without succumbing to corporate secrecy. Managing Director Clare Durrett recognized that traditional software silos would only delay breakthroughs and orchestrated a crucial strategic partnership with Microsoft to help build Neuromine, an open-access data portal hosted natively on the Azure cloud platform. Driven by a direct mandate from the ALS community, Durrett spared no effort to provide researchers worldwide with immediate access to the repository.

Managing the scientific integrity of the massive cloud infrastructure required dedicated bioinformatics expertise. Dr. Terri Thompson stepped into the role of Program Director of Data Management to oversee the colossal influx of multi-omics information. Drawing on her critical experience standardizing complex datasets for the NASA GeneLab program, Thompson directs the rigorous quality control and harmonization of the repository. Her leadership ensures that the 150 terabytes of biological data act as a highly reliable, constantly updated resource, breaking down technical barriers for global researchers. Thompson’s team also ensured the deployment of robust architectural safeguards like Microsoft Entra ID, guaranteeing that the highly sensitive biological information remains completely anonymized and secure.

Building upon the success of the global repository, the research has expanded to investigate an unresolved statistical correlation: military veterans, first responders, and high-performing athletes develop ALS at significantly higher rates than the general public. To uncover the specific genetic and environmental factors driving this elevated risk, Answer ALS, Augie’s Quest, and the ALS Therapy Development Institute launched the Champion Insights program. In February 2026, Steve Gleason served as the initiative’s first participant, utilizing a remote blood collection kit to officially open enrollment for the targeted nationwide study.

The original seventeen-page blueprint that became the basis for Answer ALS has now materialized into the world’s largest coordinated and collaborative ALS research project. The Neuromine Data Portal actively democratizes access to the information, freely distributing over 150 terabytes of harmonized data to the global scientific community and sparking nearly 600 independent research projects worldwide. A recent integration of the ALS Therapy Development Institute’s ARC study effectively doubled the available clinical and biological data, providing scientists with unparalleled statistical power. The collaborative infrastructure can shorten standard target identification timelines by an estimated 65 percent. The invisible walls built around scientific research are beginning to crumble, allowing a global network of the world’s best minds to study ALS with a clear, collective focus, ensuring future generations encounter ALS in history books rather than medical charts.